SecBot SecBot
8-K ·Filed Apr 24, 2026

LUCD

Lucid Diagnostics Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001493152-26-018926
8-K context-dependent: Items 7.01, 8.01
Actionable Insight • Neutral

Monitor upcoming financial reports for how the company allocates the new capital and whether it improves operational metrics. The dilution from issuing 18 million new shares may pressure the stock price despite the cash infusion.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
LUCD ▼ -10.85% at T+60d
NEUTRAL call -10.85% · α vs SPY -15.63% · entry $1.06 → $0.9450
Entry = T+0 close
Apr 24, 2026
via day close
T+1d
-1.89%
call -1.89% · α -1.40%
$1.04
settled 6mo ago
T+5d
+2.83%
call +2.83% · α +2.43%
$1.09
settled 6mo ago
T+20d
+4.72%
call +4.72% · α -0.24%
$1.11
settled 5mo ago
T+60d
-10.85%
call -10.85% · α -15.63%
$0.9450
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Lucid Diagnostics Inc. (LUCD) closed an underwritten public offering of 18 million shares at $1.00 per share, raising $18 million in gross proceeds and approximately $16.8 million in net proceeds. The company plans to use the funds for working capital and general corporate purposes.

Key Facts

  • Closed an underwritten offering of 18,000,000 shares at $1.00 per share
  • Gross proceeds of $18 million, net proceeds of approximately $16.8 million
  • Proceeds to be used for working capital and general corporate purposes
  • Offering was anchored by a $15 million investment from a fundamental institutional investor
  • Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners

Financial Impact

Raises $16.8 million in net proceeds through issuance of 18 million shares, representing significant dilution to existing shareholders

dilutioncashequity

Risk Factors

  • Significant shareholder dilution from issuing 18 million new shares
  • No specific strategic use of funds disclosed beyond general working capital needs
  • Execution risk in deploying capital effectively to improve business performance

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-018926
Exhibit: ex99-1.htm0001493152-26-018926
Document: 0001493152-26-018926-index-headers.html0001493152-26-018926
Document: 0001493152-26-018926-index.html0001493152-26-018926
Document: 0001493152-26-018926.txt0001493152-26-018926
7 reports for LUCD
Performance horizon
50% Hit rate @ T+1 2 of 4 directional calls Went positive at some point 2 of 4 best @ T+1▲ +6.63%Oct 16, 2026
Filters
Rows
Reports for LUCD — sortable, filterable
TypeNow
Oct 22, 2026
4d ago
8-K
BEARISH ★ 6/10
$0.4110 $0.5007▼ −21.82%▼ −21.11%$0.5010 (−21.90%)
Oct 16, 2026
10d ago
8-K
BEARISH ★ 7/10
$0.3770 $0.3520▲ +6.63%▲ +6.97%$0.5010 (−32.89%)
Sep 22, 2026
4w ago
8-K
BULLISH ★ 5/10
$0.8930 $0.8390▼ −6.05%▼ −5.33%$0.5010 (−43.90%)
Aug 13, 2026
10w ago
8-K
MIXED ★ 5/10
$0.9649 $0.9677▲ +0.29%▲ +0.49%$0.5010 (−48.08%)
May 14, 2026
23w ago
8-K
BEARISH ★ 5/10
$1.02 $0.9910▲ +2.84%▲ +1.62%$0.5010 (+50.88%)
Apr 24, 2026
26w ago
8-K
NEUTRAL ★ 5/10
$1.06 $1.04▼ −1.89%▼ −1.40%$0.5010 (−52.74%)
Apr 23, 2026
26w ago
8-K
NEUTRAL ★ 5/10
$1.07 $1.06▼ −0.93%▼ −1.10%$0.5010 (−53.18%)
Showing 7 of 7

US Market Status

Market Closed — Opens in 3h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026